Compare YELP & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | MGTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2011 | 2018 |
| Metric | YELP | MGTX |
|---|---|---|
| Price | $23.02 | $13.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $29.17 | $24.57 |
| AVG Volume (30 Days) | ★ 1.0M | 588.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.15 | ★ 33.02 |
| EPS | 0.86 | ★ 1.30 |
| Revenue | ★ $1,464,955,000.00 | $81,391,000.00 |
| Revenue This Year | $2.19 | $141.38 |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | $26.17 | ★ $10.88 |
| Revenue Growth | 3.75 | ★ 144.57 |
| 52 Week Low | $19.60 | $6.62 |
| 52 Week High | $34.49 | $15.35 |
| Indicator | YELP | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 55.37 |
| Support Level | $21.52 | $7.04 |
| Resistance Level | $24.66 | $15.35 |
| Average True Range (ATR) | 0.90 | 0.76 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 26.01 | 53.08 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.